- Home
- NXTC vs WWR Comparison
NXTC vs WWR Comparison
Compare NXTC & WWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- WWR
- Stock Information
- Founded
- NXTC 2015
- WWR 1977
- Country
- NXTC United States
- WWR United States
- Employees
- NXTC N/A
- WWR N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- WWR Metal Mining
- Sector
- NXTC Health Care
- WWR Basic Materials
- Exchange
- NXTC Nasdaq
- WWR Nasdaq
- Market Cap
- NXTC 13.9M
- WWR N/A
- IPO Year
- NXTC 2019
- WWR N/A
- Fundamental
- Price
- NXTC $5.00
- WWR $0.61
- Analyst Decision
- NXTC Strong Buy
- WWR Strong Buy
- Analyst Count
- NXTC 2
- WWR 1
- Target Price
- NXTC $3.50
- WWR $2.00
- AVG Volume (30 Days)
- NXTC 341.5K
- WWR 611.9K
- Earning Date
- NXTC 07-31-2025
- WWR 08-13-2025
- Dividend Yield
- NXTC N/A
- WWR N/A
- EPS Growth
- NXTC N/A
- WWR N/A
- EPS
- NXTC N/A
- WWR N/A
- Revenue
- NXTC N/A
- WWR N/A
- Revenue This Year
- NXTC N/A
- WWR N/A
- Revenue Next Year
- NXTC N/A
- WWR N/A
- P/E Ratio
- NXTC N/A
- WWR N/A
- Revenue Growth
- NXTC N/A
- WWR N/A
- 52 Week Low
- NXTC $0.22
- WWR $0.45
- 52 Week High
- NXTC $1.82
- WWR $1.32
- Technical
- Relative Strength Index (RSI)
- NXTC 37.68
- WWR 56.90
- Support Level
- NXTC $0.42
- WWR $0.57
- Resistance Level
- NXTC $0.50
- WWR $0.63
- Average True Range (ATR)
- NXTC 0.04
- WWR 0.03
- MACD
- NXTC -0.01
- WWR -0.00
- Stochastic Oscillator
- NXTC 4.17
- WWR 71.29
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.